Paper42434745
Optimal treatment strategies for unresectable stage III EGFR-mutated non-small cell lung cancer: a systematic review and Bayesian network meta-analysis.
Yang Y and 4 others. Front Oncol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Optimal treatment strategies for unresectable stage III EGFR-mutated non-small cell lung cancer: a systematic review and Bayesian network meta-analysis. Papers, record 42434745. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42434745
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Optimal treatment strategies for unresectable stage III EGFR-mutated non-small cell lung cancer: a systematic review and Bayesian network meta-analysis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38909011 | Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched-Pair Cohort Study Using a Nationwide Inpatient Database. | Clin Lung Cancer | 2024 | https://conductscience.org/library/papers/38909011 | PubMed |
| 2 | 34699691 | The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation. | Cancer Commun (Lond) | 2021 | https://conductscience.org/library/papers/34699691 | PubMed |
| 3 | 41697515 | Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China. | Adv Ther | 2026 | https://conductscience.org/library/papers/41697515 | PubMed |
| 4 | 41512290 | Targeting common EGFR mutations in non-small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors. | J Natl Cancer Inst | 2026 | https://conductscience.org/library/papers/41512290 | PubMed |
| 5 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 6 | 39958229 | Clinical features and outcomes of unresectable locally advanced lung adenocarcinoma with uncommon EGFR mutations: a retrospective multi-center Chinese study. | Transl Lung Cancer Res | 2025 | https://conductscience.org/library/papers/39958229 | PubMed |
| 7 | 40086102 | The evolving landscape of stage III unresectable non-small cell lung cancer "between lights and shadows". | Cancer Treat Rev | 2025 | https://conductscience.org/library/papers/40086102 | PubMed |
| 8 | 30152040 | Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR. | Thorac Cancer | 2018 | https://conductscience.org/library/papers/30152040 | PubMed |
| 9 | 41820542 | Assessment of pneumonitis in patients with lung cancer undergoing radioimmunotherapy and immune checkpoint inhibitor rechallenge. | Commun Med (Lond) | 2026 | https://conductscience.org/library/papers/41820542 | PubMed |
| 10 | 33569332 | Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. | Transl Lung Cancer Res | 2021 | https://conductscience.org/library/papers/33569332 | PubMed |
| 11 | 41419100 | Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancer. | Cancer Lett | 2026 | https://conductscience.org/library/papers/41419100 | PubMed |
| 12 | 33588109 | Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. | J Thorac Oncol | 2021 | https://conductscience.org/library/papers/33588109 | PubMed |
| 13 | 40136350 | Lung Cancer: Targeted Therapy in 2025. | Curr Oncol | 2025 | https://conductscience.org/library/papers/40136350 | PubMed |
| 14 | 33220395 | Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial. | Int J Radiat Oncol Biol Phys | 2021 | https://conductscience.org/library/papers/33220395 | PubMed |
| 15 | 36841540 | Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC. | J Thorac Oncol | 2023 | https://conductscience.org/library/papers/36841540 | PubMed |
| 16 | 38828946 | Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. | N Engl J Med | 2024 | https://conductscience.org/library/papers/38828946 | PubMed |
| 17 | 40480013 | Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis. | Lung Cancer | 2025 | https://conductscience.org/library/papers/40480013 | PubMed |
| 18 | 34799993 | Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors. | Thorac Cancer | 2022 | https://conductscience.org/library/papers/34799993 | PubMed |
| 19 | 38278303 | Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. | J Thorac Oncol | 2024 | https://conductscience.org/library/papers/38278303 | PubMed |
| 20 | 40313586 | LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154). | Lung Cancer (Auckl) | 2025 | https://conductscience.org/library/papers/40313586 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42434745
GET https://conductscience.org/api/papers/v1/42434745/references?page=2